Financial Survey: AxoGen (AXGN) versus Vaso (VASO)

AxoGen (NASDAQ:AXGN) and Vaso (OTCMKTS:VASO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares AxoGen and Vaso’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AxoGen -25.39% -18.17% -14.44%
Vaso -4.65% -46.63% -6.69%

Analyst Ratings

This is a breakdown of recent ratings for AxoGen and Vaso, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen 0 1 6 0 2.86
Vaso 0 0 0 0 N/A

AxoGen currently has a consensus price target of $44.80, suggesting a potential upside of 175.86%. Given AxoGen’s higher possible upside, analysts clearly believe AxoGen is more favorable than Vaso.

Institutional and Insider Ownership

88.6% of AxoGen shares are owned by institutional investors. 7.9% of AxoGen shares are owned by company insiders. Comparatively, 9.1% of Vaso shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares AxoGen and Vaso’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AxoGen $60.43 million 10.30 -$10.44 million ($0.31) -52.39
Vaso $72.78 million 0.08 -$4.53 million N/A N/A

Vaso has higher revenue and earnings than AxoGen.

Volatility & Risk

AxoGen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Vaso has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Summary

Vaso beats AxoGen on 6 of the 11 factors compared between the two stocks.

AxoGen Company Profile

AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Vaso Company Profile

Vaso Corporation operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging capital equipment, GEHC service agreements, and GEHC and third party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices. This segment provides Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for physiological signals, such as ECG and blood pressure; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsaion therapy systems that are used for non-invasive, outpatient treatment of ischemic heart disease, as well as in-service and training support. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was founded in 1987 and is headquartered in Plainview, New York.

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply